US and India to join hands on the grounds of Intellectual Property Rights

Dec 2022

After US President Donald Trump’s visit in India from February 24 to 25th February, India and the US have opted for an agreement relating to intellectual property rights or IPR. As a result of this, the cabinet sanctioned MoU with the US pertaining to IPRs, relevant to information and broadcasting as has been stated by Minister Prakash Javadekar.

Officials are of the opinion that the agreement is a knowledge-sharing one that will enhance the functioning of the IPR system between the two parties involved in the agreement. The pack has been triggered due to the fact that India has dropped to 40th position in US Chamber’s International IP Index. In addition to this, the country is still in the US’s priority list. Due to this, there are some trade barriers with US companies on account of IP laws of other countries.

Putting beside the trade barriers, it requires the smooth and active cooperation of the US and India, which can improve the flow of IPR systems. Similar MoU has also been conducted with other countries. However, considering India and the US, the agreement is important as has been stated by a senior official. However, the agreement took place after the Department of Promotion of Industry and Internal Trade decided to review IPR laws.

Another official stated that the MoU is a type of learning exercise. The time of the agreement is decided across the whole IPR program that includes the copyrights and patent issues without being specific to any of the sectors. The official further added that it does not require any law. Along with this, it will have training sessions in which concerned officials have to travel to each of the countries to study the condition of its IPR system.

The MoU has no connection with a legal commitment by the country as has been stated by experts, India needs to be careful as the US is trying to push India to withdraw Section 3 (d) of Indian Patents Act. The patent is relating to items that have little to no difference compared to its older version. It is also obstructed in case of compulsory license that involves the manufactured copies of the drugs that will help address problems of emergency. This is done as per has been stated in the trade rules.

Last year, the US was of the opinion that India does not have an effective system that can look after the unfair practices of commercial items. Also, it cannot protect any unauthorized disclosure or data or generate data as a means of better marketing strategies for the agricultural and pharma based items.

Trending Blogs

Artificial Intelligence and Intellectual Property Law

What is Artificial Intelligence? The division of Science which deals with making machines equipped with human-like intelligence to act in human-like fashion and the exhibit human capabilities is known as Artificial Intelligence (AI). Multiple disciplines like Computer Science, Psychology, Philosophy, Sociology, Mathematics, Biology and Neuron Science contribute to the development of AI. Benefits Of AI […]

The Common Law Protection Of Trade Secrets And The Need For A Statue

Introduction: A trade secret is anything you use in your business that gives you an advantage over your competitors. A trade secret can be a recipe, process, formula, strategy, technique or device that your competitors do not know, do not have, and cannot use. With development in technology, as well as the ease of sharing, […]

Trademarking surnames

Having difficult surnames may be challenging to explain others and also when you want to register the name as trademark. As per the trademark and merchandise act of 1958, it is stated that a mark can be refused if one choose a personal name or surname. Though, there is no such clear specification in the […]

US and India to join hands on the grounds of Intellectual Property Rights

Pharma Companies File 15% of Patents in India

The Indian Pharma industry is primarily known for its Generic Drugs. But recently, to push its value higher in the market, the Indian pharmaceutical industry is investing more in research and development of new drugs along with increasing the potency of the existing ones to move up the value chain. From 2013-2015, out of the […]

Blockchain Technology: Is it Building a Brighter Future

What is Blockchain Technology? The Blockchain is an incorruptible digital ledger of transactions that can be programmed to record virtually everything of value. So a blockchain is a continuously growing list of records called blocks, which are linked and secured. It protects the identities of the users. Although transactions on the blockchain are not completely […]

India dropped to 40th position in International Intellectual Property Index

India has fallen to 40th position in the International Intellectual Property Index. This index helps know about the IP climate in the 53 global economies of the present year. This is as per the report US Chamber of Commerce’s Global Innovation Policy Center. As per last year’s report, India has been ranked in the 36th […]

The Big Push to Reform Music Copyright for the Digital Age

Music creators of the present digital age should be aware of the copyright issues better due to different reasons. Music is made available on different websites, and it is necessary to prevent the increasing problem of infringement. Pertaining to this, a number of bills are proposed in Congress that can enhance royalty payment for the […]

Intellectual Property and its Role in the Pharmaceutical Industry

Intellectual property rights are considered to be an important asset of any corporate unit. It is an indication of the creation of mind and the work that makes one entity different from the other. With better IP or intellectual rights, it would be easy to promote the possible innovations and this would be useful in […]

Drug Patents and Generic Pharmaceutical Drugs

When a drug is manufactured and released to the market in the initial period, it is sold under a certain brand names and can only be availed from a pharmacy after being prescribed by the doctor. The patent of the drug is owned by a few brands who are the only eligible brands to manufacture […]